MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eururo.2026.02.016

Медицинская библиотека · European urology · 2026

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

Economides Minas P, O'Donnell Peter H, Alva Ajjai S, Milowsky Matthew I, Kollmeier Marisa, Niglio Scot, Persily Jesse, Sweis Randy F, Rose Tracy, Iyer Gopakumar, Spratt Daniel, Palmbos Phillip, Hochman Tsivia, Goldberg Judith D, Francese Kaitlyn, Griglun Sarah, Leis Dayna, Steinberg Gary D, Wysock James, Schiff Peter B, Sanfilippo Nicholas J, Taneja Samir S, Wise David R, Huang William C, Balar Arjun V

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVE

Trimodality therapy (TMT) is an accepted bladder-preserving option for selected patients with muscle-invasive bladder cancer (MIBC). Pembrolizumab has demonstrated activity in MIBC and may enhance the effects of chemotherapy and radiation. We evaluated the safety and efficacy of adding pembrolizumab to TMT.

METHODS

In this multicenter phase 2 trial, patients with MIBC received one dose of pembrolizumab followed by maximal transurethral resection, then definitive bladder radiation with concurrent low-dose gemcitabine and pembrolizumab every 3 wk for three doses. The primary end point was 2-yr bladder-intact disease-free survival (BIDFS). Secondary end points included safety, metastasis-free survival (MFS), and overall survival (OS).

KEY FINDINGS AND LIMITATIONS: Fifty-four patients were enrolled, including 48 in the efficacy cohort; 67% had clinical stage T2 disease. The 2-yr BIDFS was 60% (95% confidence interval [CI], 45-73). Two-yr MFS and OS were 81% (95% CI, 66-92) and 83% (95% CI, 69-91), respectively. Grade ≥3 treatment-related adverse events occurred in 25% of patients. Limitations include the single-arm design and modest sample size.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Pembrolizumab combined with gemcitabine-based chemoradiation was feasible and showed efficacy comparable to standard TMT. Ongoing phase 3 trials will further define its role in bladder preservation.

Для цитирования: Economides Minas P, O'Donnell Peter H, Alva Ajjai S, Milowsky Matthew I, Kollmeier Marisa, Niglio Scot, Persily Jesse, Sweis Randy F, Rose Tracy, Iyer Gopakumar, Spratt Daniel, Palmbos Phillip, Hochman Tsivia, Goldberg Judith D, Francese Kaitlyn, Griglun Sarah, Leis Dayna, Steinberg Gary D, Wysock James, Schiff Peter B, Sanfilippo Nicholas J, Taneja Samir S, Wise David R, Huang William C, Balar Arjun V. Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.. European urology. 2026. DOI: 10.1016/j.eururo.2026.02.016.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.